NASDAQ$CRBU
Caribou Biosciences Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Caribou Biosciences reported its Q1 2025 earnings, showing a decrease in net loss and total other income compared to the previous year, while total assets also decreased.
Caribou Biosciences, Inc. reported a net loss of $39.991 million for Q1 2025, an improvement from the $41.234 million net loss in Q1 2024. Total operating expenses decreased to $45.266 million from $48.431 million in the prior year. Total assets as of March 31, 2025, were $273.656 million, down from $313.313 million at the end of 2024.
- Net loss improved to $39.991 million in Q1 2025 from $41.234 million in Q1 2024.
- Total operating expenses decreased by $3.165 million, driven by lower general and administrative expenses.
- Total assets decreased to $273.656 million as of March 31, 2025, from $313.313 million at December 31, 2024.
- Cash and cash equivalents increased to $29.417 million from $16.293 million at the end of 2024.
Headline financials
Revenue & EPS history
Caribou Biosciences · Revenue · Quarterly
$2.35M
Revenue by segment
Caribou Biosciences · $3.76M total across 1 segment · Q2 2023
- Licensing & collaboration$3.76M-10.6%100.0%
Forward guidance
Caribou Biosciences expects to continue incurring substantial losses and will need to raise additional capital to fund operations until profitability is achieved. The company's existing cash, cash equivalents, and marketable securities are projected to be sufficient for at least the next 12 months. Future funding requirements are dependent on various factors including clinical trial progress, regulatory approvals, and market conditions.
Tailwinds
- Existing cash, cash equivalents, and marketable securities are expected to fund operations for at least the next 12 months.
- Potential for future equity financing, debt financing, collaborations, and strategic alliances to raise capital.
- Advancement of clinical trials for CAR-T cell therapy product candidates.
- Expansion of manufacturing capabilities and supply chain capacity.
- Continued efforts to expand, maintain, enforce, and defend intellectual property portfolio.
Headwinds
- Continued substantial losses and negative cash flows from operations are expected.
- Ability to achieve and sustain profitability depends on successful development and commercialization of product candidates.
- Uncertainty regarding the nature, timing, and costs to complete product candidate development.
- Potential for delays, challenges, or other issues in clinical trials, including failure to meet endpoints or safety issues.
- Risk of delisting from Nasdaq if minimum bid price requirements are not met, potentially impacting liquidity and ability to raise equity financing.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2025
-0.8%
Avg return
Earnings day
+0.9%
Avg return
5 days after
-5.2%
Avg return
30 days after
53%
10 / 19 earnings
Positive
+11.1%
Q2 2021
Best reaction
-32.3%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.1% | +4.1% | -1.5% | |
| Q4 2025 | +6.5% | +15.2% | +13.5% | |
| Q3 2025 | -12.1% | -17.3% | -20.8% | |
| Q1 2025 | +10.5% | +16.7% | +19.4% | |
| Q4 2024 | +0.1% | -8.6% | -22.2% | |
| Q3 2024 | +8.6% | +9.0% | -16.8% | |
| Q2 2024 | -3.1% | -0.8% | -6.4% | |
| Q1 2024 | -8.6% | -7.6% | -45.4% | |
| Q4 2023 | -32.3% | -27.6% | -41.4% | |
| Q3 2023 | -5.0% | -19.3% | +24.7% | |
| Q2 2023 | +5.2% | +5.8% | -12.0% | |
| Q1 2023 | +9.3% | -2.1% | +4.0% | |
| Q4 2022 | -11.8% | -11.4% | -9.9% | |
| Q3 2022 | +3.9% | +15.0% | +2.4% | |
| Q2 2022 | +10.1% | +17.3% | +40.7% | |
| Q1 2022 | -0.5% | +22.4% | +23.7% | |
| Q4 2021 | +2.6% | -5.6% | -16.1% | |
| Q3 2021 | -4.9% | -0.5% | -18.2% | |
| Q2 2021 | +11.1% | +12.3% | -17.3% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro